ClinicalTrials.gg
RecruitingNCT05047198CARA-VT RCTUpdated Sep 30, 2026

Catheter Ablation Versus Radio-Ablation for Ventricular Tachycardia: a Randomized Controlled Trial

A Phase 3 interventional study of Control - Catheter Ablation for VT and Treatment - Non-Invasive Radio Ablation for VT in Ventricular Tachycardia, sponsored by Ottawa Heart Institute Research Corporation. Recruiting at 1 site in Canada. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Ottawa Heart Institute Research Corporation · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Tachycardia, Ventricular with a site in Canada — 17 open to participants now, 19 under way, 2 of them phase 3. Tachycardia, Ventricular · Canada.

Planned enrollment
14th of 39
244 · median 130
Started
2022
the only one that year
Phase 3
9 of 54
2 open now
Primary completion
2026-12
later than 4 of 18 live
Registered
40th of 54
by date
Lead sponsor
4 of 54
Ottawa Heart Institute Research Corporation

Among the 54 studies in Tachycardia, Ventricular with a site in Canada, this one is the 14th largest by planned enrollment of the 39 interventional ones that give a count, is the only one that started in 2022, is one of 9 in phase 3, reaches primary completion later than 4 of the 18 other live ones, and was the 40th registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

17 of the 54 studies in Tachycardia, Ventricular with a site in Canada are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Tachycardia, Ventricular with a site in Canada, or all of them as a file.
02

Study summary

This study compares two arms - the current standard of care catheter ablation for Ventricular Tachycardia compared to stereotactic radiotherapy to non-invasively ablate ventricular tachycardia using a novel non-invasive ECG based body surface mapping technology. This allows investigators to identify ventricular tachycardia circuits to target for subsequent radio ablation. To summarize, the current standard of care invasive catheter ablation to the non-invasive radio ablation.

Read the detailed description

Currently patients suffering Ventricular Tachycardia (VT) are offered drugs, such as Amiodarone, Implantable cardioverter defibrillatorf (ICD) implant and catheter ablation. Although effective drugs have side effects, ICD shocks are painful and catheter ablation is arduous for patients at high risk of complications. Catheter ablation is currently the gold standard treatment for recurrent VT despite anti-arrhythmic drugs (AADs).

Catheter ablation (CA) was initially developed in the 1980s following the successful treatment of VT by surgical resection of myocardial scarring in structural heart disease. After thorough clinical evaluation and medical stabilization, imaging is performed to identify culprit areas for ablation and to stratify risk of intervention. Pre procedural imaging in patients with ICDs in situ involves Echocardiography, Computerized Tomography (CT) scanning and Positron Emission Tomography (PET) imaging in order to assess cardiac function, ischemia, inflammation and scarring. If necessary mechanical circulatory support, Left Ventricular Assist Devices (LVAD) and/ or Extra Corporeal Membrane Oxygenation (ECMO) can be used to sustain cardiac output during VT induction and mapping.

Radiofrequency (RF) energy delivered via catheter to the arrhythmogenic target results in local resistive heating and is performed under sedation or anesthesia using multiple catheters placed in the heart while the patient is anticoagulated. Conventional approaches involve advancing multiple catheters via Femoral veins and/or arteries under a combination of fluoroscopic, ultrasound and electroanatomic guidance. Ablation targets include an arrhythmogenic focus or the critical isthmus of the VT circuit and/ or substrate identified on preprocedural imaging or low voltage areas, "scar", identified during endocardial mapping. CA procedures for VT are often long, averaging 5 hours duration reported in clinical trials, with prolonged procedures being associated with adverse outcomes and 30 day complication rates, including death, of 7- 13%.

Vulnerable patients requiring circulatory support or at high risk of recurrence and death following catheter ablation can be identified pre-operatively. Of all patients undergoing CA for VT, more than a third are "high risk" with a one year risk of death of >20%. Patients older than 65 with prior catheter ablation and recurrent VT with impaired left ventricular ejection fraction ≤35% have 90 day VT recurrence rates of 30% and mortality of 20%.

Patients with comorbidities such as Diabetes or COPD and those presenting in VT storm are also at high risk of hemodynamic compromise and death following Catheter Ablation. Without prophylactic LVAD placement, patients at high risk of haemodynamic instability (PAINESD score ≥ 15) suffer 30% death at thirty days with 41% VT recurrence post CA. It is these "high risk" patients that we believe will benefit from a non-invasive RA approach.

Patients undergoing a non-invasive Radio-Ablation (RA) procedure for VT similarly require medical stabilization and multimodal imaging prior to treatment. Instead of an invasive catheter-based electrophysiology study (EPS) and ablation, a non-invasive EPS (NIPS) is performed under light sedation using ECGi mapping. This short procedure, averaging 40 minutes, requiring only the placement of an IV cannula for light sedation, uses the ICD to stimulate VT which is mapped in real time using the CardioInsight ECGi mapping system.

The multimodal imaging data is digitally fused and then combined with the ECGi data to identify the VT circuit(s) and to target the arrhythmogenic tissue for radio-ablation. This analogue process is performed off- line by a committee of Cardiac Imaging and EP Cardiologists and a Radiation Oncologist. Once the target(s) are identified, the treatment plan is sent to Medical Physics for alignment on a 4D planning CT performed with breath holding in the radiotherapy suite. Final treatment targets are reviewed by the local treating team and discussed with our collaborators in St Louis. Thereafter the patient is booked for a 15 minute out-patient radiotherapy treatment performed on a standard linear accelerator.

Photon radiotherapy, as commonly used in cancer therapeutics across Canada, is guided using a cone beam onto the cardiac target(s). A single fraction of 25 Gy is delivered painlessly over 15 minutes. Although minor side effects have been reported, serious adverse events are rare and no ICD related issues have been described. No deleterious effects on cardiac function (LVEF) have been observed although approximately (5/65? TBC) patients have required a two week course of oral glucocorticoid therapy for symptomatic inflammation such as pericarditis or pneumonitis post RA25. All patients are treated with Rivaroxaban 20 mg po as prophylaxis against thromboembolism for thirty days post RA.

Radioablation is a novel procedure and long-term outcomes remain unknown. Reduction in VT is reported to be 85-92% up to 6 months post RA and in the ENCORE -VT study 17 of 19 patients were free from ICD shocks at 6 months. In the only prospective study of RA for VT, patients reported an improvement in quality of life in 5 of 9 domains remaining unchanged in 4. Long term safety data continue to be collected but cardiac irradiation \<40 Gy has been historically associated with an approximate 1% excess mortality over years to decades in those receiving treatment for breast or lung cancer. This is in the context of a total mortality of 28% over 24 months of follow up in those undergoing CA for recurrent VT in Canada.

03

Conditions studied

  • Ventricular Tachycardia
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient aged ≥55 years of age
  2. Cardiomyopathy ( ≤ 35% and ICD in situ) AND
  3. Recurrent VT events despite previous CA OR
  4. VT events requiring intervention and PAINESD score ≥ 15

Exclusion criteria

Exclusion Criteria:

  1. Patients with Class IV heart failure \&/ or with LVAD in situ
  2. Patients not expected to live for more than one year for any reason
  3. Patients who have previously received thoracic radiotherapy
  4. Patients who are enrolled in another randomized clinical trial
  5. Patients who are unable or unwilling to provide
  6. Patients aged ≤54 years of age
  7. Pregnancy (all women of child bearing age and potential will have a negative β-HCG test before enrollment)
  8. Breastfeeding
  9. Women of childbearing age who refuse to use a highly effective and medically acceptable form of (IUD, sterilization, birth control implant or birth control pill) throughout the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
244 participants (estimated)

Study arms

  • Active comparator
    Control

    Catheter Ablation using invasive mapping

    Procedure: Control - Catheter Ablation for VT

  • Experimental
    Treatment

    Radio-ablation using non-invasive mapping

    Procedure: Treatment - Non-Invasive Radio Ablation for VT

Interventions

  • ProcedureControl - Catheter Ablation for VT

    Currently standard of care involves surgical resection of myocardial scarring in structural heart disease. Imaging is performed to identify culprit areas for ablation, pre procedural imaging involves echocardiography, CT scanning and PET imaging to assess cardiac function, ischemia, inflammation and scarring. Radiofrequency energy is delivered via catheter to the targets and is performed under sedation or anesthesia using multiple catheters placed in the heart while the patient is anticoagulated. A conventional approach will be used advancing multiple catheters via femoral veins and/or arteries under a combination of fluoroscopic, ultrasound and electroanatomic guidance. Ablation targets include an arrhythmogenic focus or the critical isthmus of the VT circuit and/ or substrate identified on preprocedural imaging or low voltage areas, "scar", identified during endocardial mapping. CA procedures for VT are often long, averaging approximately 5 hours .

  • ProcedureTreatment - Non-Invasive Radio Ablation for VT

    Patients undergoing a non-invasive RA procedure for VT similarly require medical stabilization and multimodal imaging prior to treatment. A non-invasive electrophysiology study is performed under light sedation using ECGi mapping. This procedure requires only the placement of an IV cannula for light sedation, uses the ICD to stimulate VT which is mapped in real time using the ECGi mapping system. The multimodal imaging data is digitally fused and combined with the ECGi data to identify the VT circuit(s) and to attain the targets for radio-ablation. This analogue process is performed off-line by a physician team. The treatment plan is sent for alignment on a 4D planning CT performed with breath holding in the radiotherapy suite. Final treatment targets are reviewed by the local treating team and discussed with our collaborators remotely. Thereafter the patient is booked for a 15 minute out-patient radiotherapy treatment performed on a standard linear accelerator.

06

What researchers measure

Primary outcomes

  1. Time to composite event

    Composite event including death at any time, appropriate ICD shock after 14 days, ventricular tachycardia storm after 14 days, treated sustained ventricular tachycardia below the detection rate of the ICD after 14 days

    Time frame: 14 days

Secondary outcomes

  1. Appropriate ICD ATP at any time or after 14 days

    Any appropriate therapy delivered from the ICD at least 14 days post randomization

    Time frame: at any time or after 14 days

  2. Appropriate shocks

    Appropriate ICD shocks at any time post randomization

    Time frame: at any time or after 14 days

  3. VT storm at any time or after 14 days

    3 or more episodes of VT occurring within 24 hours at any time post randomization

    Time frame: at any time or after 14 days

  4. Sustained VT not treated by ICD at any time or after 14 days

    Time to sustained VT treated with appropriate any type of manual cardioversion after 14 days Any sustained VT greater than 30 seconds requiring manual cardioversion (ICD, external or pharmacologic)

    Time frame: at any time or after 14 days

  5. Inappropriate ICD shocks at any time or after 14 days

    All inappropriate shocks from the ICD at any time post randomization

    Time frame: at any time or after 14 days

  6. Any ICD shock at any time or after 14 days

    Both appropriate and inappropriate shocks from the ICD at any time post randomization

    Time frame: at any time or after 14 days

  7. Any ventricular arrhythmia event at any time or after 14 days

    All ventricular arrhythmias including a composite of: appropriate ATP, appropriate shock, sustained VT not treated by ICD, external cardioversion, or pharmacologic cardioversion), VT storm/incessant VT. (composite of appropriate ATP, appropriate shock, sustained VT not treated by ICD, external cardioversion, or pharmacologic cardioversion)

    Time frame: at any time or after 14 days

  8. Number of ICD shocks (all cause)

    The number of all shocks from any cause will be calculated

    Time frame: 3 years

  9. Number of Anti-tachycardia pacing (ATP)

    The total of all ATP delivered from the ICD will be calculated

    Time frame: 3 years

  10. Number of ICD appropriate therapy

    Total number of therapies which received appropriate ICD therapy

    Time frame: 3 years

  11. Number of VT storm events

    Total number of VT storms (3 episodes of VT within 24 hours)/ incessant VT will be calculated

    Time frame: 3 years

  12. Number of ventricular arrhythmia events

    This is a composite of appropriate ATP, appropriate shock, sustained VT not treated by ICD, external cardioversion, or pharmacologic cardioversion, or VT storm/incessant VT. VT events which do not terminate despite exhausting ICD therapies will be considered incessant VT and included within the definition of VT storm.

    Time frame: 3 years

  13. Hospital admission for cardiac causes

    Hospitalizations greater than 24 hours due to a cardiovascular cause.

    Time frame: 3 years

  14. Heart Failure decompensation /death

    LVEF and RVEF assessed on 6-month and 24 month echocardiogram (absolute and delta compared to baseline).

    Time frame: 3 years

  15. Procedural complications and/ or antiarrhythmic drug adverse effects

    and Periprocedural complications and adverse drug reactions will be assessed, any dose change or discontinuation of anti-arrhythmic medication due to abnormal blood tests (including kidney function, liver function, thyroid function) or any perceived side effects.

    Time frame: 3 years

  16. Patient Quality of life - SF36

    Will include responses from the Short Form 36

    Time frame: 3 years

  17. Cost-effectiveness

    Quality adjusted life years (QALYs) will be derived from the case report forms and the questionnaires

    Time frame: 3 years

  18. Escalation and De-escalation of antiarrhythmic medication

    Any increase or decrease in the dosage of antiarrhythmic medication either due to inefficacy or side effects will be assessed and reviewed.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Dec 2026, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2021
First posted
Sep 17, 2021
StartActual
Dec 6, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 15, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05047198
Responsible party
Sponsor
First posted
Sep 17, 2021
Start date
Dec 6, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Calum Redpath
Contact
credpath@ottawaheart.ca
6136967000
Tammy Knight
Contact
tknight@ottawaheart.ca
6136967000 ext. 19080
Calum Redpath
principal investigator · Ottawa Heart Institute Research Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion